EyePoint to Present at Guggenheim SMID Cap Biotech Conference

Core Insights - EyePoint Pharmaceuticals, Inc. is focused on developing innovative therapeutics for serious retinal diseases and will have its CEO participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 [1][2] Company Overview - EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company that utilizes proprietary bioerodible Durasert E technology for sustained intraocular drug delivery [3] - The lead product candidate, DURAVYU (formerly EYP-1901), is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and Phase 2 trials for diabetic macular edema (DME) [3][4] - Full topline data from the Phase 2 trial in DME is expected in Q1 2025, with topline data from Phase 3 trials in wet AMD anticipated in 2026 [3] Product Pipeline - Pipeline includes EYP-2301, a TIE-2 agonist, and razuprotafib, both formulated in Durasert E to potentially enhance outcomes in serious retinal diseases [4] - The Durasert drug delivery technology has been safely used in thousands of patient eyes across four FDA-approved products [4] Licensing and Regulatory Status - Vorolanib, a key component of DURAVYU, is exclusively licensed to EyePoint for localized treatment of ophthalmic diseases outside of certain Asian markets [5] - DURAVYU has been conditionally accepted by the FDA as the proprietary name for EYP-1901, but it remains an investigational product and has not yet received FDA approval [5]